Shanghai’s Everest Medicines (HK: 1952) and Gilead Sciences (Nasdaq: GILD) have announced positive data from a Chinese Phase IIb trial of sacituzumab govitecan.
The antibody-drug conjugate (ADC), which is approved and marketed as Trodelvy in the USA, met its primary endpoint of overall response rate in metastatic triple-negative breast cancer (TNBC).
The EVER-132-001 study is a single-arm, multicenter registrational study testing the ADC in the third-line setting.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze